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Abstract
There are currently no biological tests that differentiate patients with bipolar disorder (BPD) from healthy controls.
While there is evidence that peripheral gene expression differences between patients and controls can be utilized as
biomarkers for psychiatric illness, it is unclear whether current use or residual effects of antipsychotic and mood
stabilizer medication drives much of the differential transcription. We therefore tested whether expression changes in
first-episode, never-medicated BPD patients, can contribute to a biological classifier that is less influenced by
medication and could potentially form a practicable biomarker assay for BPD. We employed microarray technology to
measure global leukocyte gene expression in first-episode (n=3) and currently medicated BPD patients (n=26), and
matched healthy controls (n=25). Following an initial feature selection of the microarray data, we developed a cross-
validated 10-gene model that was able to correctly predict the diagnostic group of the training sample (26 medicated
patients and 12 controls), with 89% sensitivity and 75% specificity (p<0.001). The 10-gene predictor was further
explored via testing on an independent cohort consisting of three pairs of monozygotic twins discordant for BPD, plus
the original enrichment sample cohort (the three never-medicated BPD patients and 13 matched control subjects),
and a sample of experimental replicates (n=34). 83% of the independent test sample was correctly predicted, with a
sensitivity of 67% and specificity of 100% (although this result did not reach statistical significance). Additionally, 88%
of sample diagnostic classes were classified correctly for both the enrichment (p=0.015) and the replicate samples
(p<0.001). We have developed a peripheral gene expression biomarker profile, that can classify healthy controls from
patients with BPD receiving antipsychotic or mood stabilizing medication, which has both high sensitivity and
specificity. Moreover, assay of three first-episode patients who had never received such medications, to first enrich
the expression dataset for disease-related genes independent of medication effects, and then to test the 10-gene
predictor, validates the peripheral biomarker approach for BPD.
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Introduction
BPD, characterized by periodic episodes of depression and
mania, is a debilitating illness affecting approximately 2.6% of
the US population [1]. BPD is usually diagnosed in the mid
twenties [2], however prior to their first manic or hypomanic
episode and subsequent diagnosis, patients often experience a
long prodromal period characterized by symptoms of
depression and anxiety [3,4]. Obtaining an accurate diagnosis
during this early phase or first episode of mania is difficult;
early adulthood or adolescent mania often manifests as
atypical or dysphoric making it hard to identify, and patients
frequently deny symptoms or self-report them inaccurately [5].
In addition, clinical assessment may altogether fail to take note
of any past episodes of mania [6], and consequently levels of
misdiagnosis are high [7–9]. For example, studies have
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e69082
documented levels of BPD underdiagnosis at approximately
40% [10,11], which persists even when a diagnosis is made
after the first episode of mania [11], while more recently, BPD
overdiagnosis was reported in 50% of patients retrospectively
assessed and may arise in part due to the aggressive mood
stabilizing drug marketing strategies [12]. These problems
contribute to the often significant lag between an individual
initially seeking treatment and then receiving a correct
diagnosis [10,13,14], and subsequently have important
treatment implications: A misdiagnosis of depression and the
resultant use of antidepressants can induce mania and mood
cycle alteration [15], while overdiagnosis can lead to
unnecessary side effects from mood stabilizer treatment, failure
to recommend the most effective treatment [13,16], and
inappropriate care during, for example, the postpartum period
[17].
The promise of an accurate test that could specifically
differentiate, from their age-matched peers, patients with BPD
early during the illness progression, has been clearly
highlighted by studies reporting that early detection and
initiation of mood stabilizing treatment in BPD patients is
associated with more favorable clinical outcomes and reduced
suicide risk [18–20]. Furthermore, both behavioral and
neuroimaging studies have supported the utility of targeting
diagnosis to the first episode of mania or before; patients both
want and are more likely to respond to treatment at this stage
[5] (and references therein), and the marked loss of brain
volume associated with later illness recurrences is still
relatively limited at the first-episode of mania [18] (and
references therein).
There is evidence that peripheral gene expression
differences in psychiatric disorder patients can be utilized as
biomarkers of psychiatric illness. Initial studies of individuals
with schizophrenia and bipolar disorder, using microarrays to
measure global gene expression in peripheral blood leukocytes
(PBLs) or peripheral mononuclear cells, have identified lists of
genes significantly differentially expressed between patients
and matched controls [21–23], that importantly could
discriminate between diagnostic groups [21,23]. More recently,
Niculescu and colleagues, also using microarray technology,
have further explored the utility of peripheral gene expression
as a biomarker for classification of symptoms, successfully
identifying a panel of genes that could differentiate BPD
patients based upon their mood state [24], or the severity of
psychotic features in three cohorts of schizophrenia and
schizoaffective disorder patients [25].
However, although this body of work suggests the promise of
such a biomarker approach, patients utilized in these studies
were ascertained later in their illness (mean age of BPD
patients was 43 [21] and 45 years [23]), and all were receiving
medication. Antipsychotic and mood stabilizer medication have
a well known immunomodulatory effect [26–29], which likely
impacts peripheral gene expression, and thus it is uncertain
whether the biomarker profiles identified largely reflect the
response to medications. Two recent and important papers
have moved towards addressing this issue [30,31]. In a study
of major depressive disorder, Spijker et al., identified a
lipopolysaccharide stimulated lymphocyte signature that could
discriminate 21 unmedicated major depressive disorder
patients from 21 controls, that was confirmed with 71.4%
specificity and 76.9% sensitivity in a replication sample of 13
patients and 14 controls [30]. Most recently, and using PBLs as
a surrogate to identify pathways dysregulated in BPD, Beech et
al., identified a list of 1180 genes significantly differentially
expressed between 20 BPD patients (mean age of 38.4 years,
of whom 9 were unmedicated), and 15 healthy controls [31],
although this large gene dataset was not further refined into a
biomarker signature and tested in follow-up cohorts.
Studies of first-episode BPD patients who have never
received medication are more limited and also somewhat
conflicting. For example, Padmos et al. reported striking data
from three subjects who were, prior to onset, correctly
predicted to develop a mood disorder based upon a monocyte
gene expression signature developed upon medicated BPD
patients [23]. However, in this study rates of mood disorder
prediction of non-affected offspring of BPD patients and healthy
children (45% and 19% respectively), were higher than
expected [4,32], particularly considering the prevalence of
mood disorders in control populations, and thus follow-up is
required to assess mood symptom onset and validate this
potentially promising biomarker profile. Conversely, a large
study of first-episode BPD patients failed to confirm utility of
potential blood biomarkers developed from assay of medicated
patients [33].
We therefore set out to test whether leukocyte gene
expression changes in first-episode, never-medicated BPD
patients, when compared to healthy controls, can contribute to
a biological classifier for bipolar disorder that is not induced by
medication, and that has the potential to be developed into a
practicable clinical biomarker assay without requiring that large
transcript numbers be assayed per sample.
Methods
Subjects and Recruitment Procedure
Ethics Statement.  The study was reviewed and approved
by the institutional review boards of the Nathan Kline Institute,
New York University Langone Medical Center, Rockland
County Department of Mental Health and Columbia University
Medical Center. Written informed consent was obtained from
all subjects in accordance with the guidelines and regulations
of the Nathan Kline Institute, New York University Langone
Medical Center, and Rockland County Department of Mental
Health institutional review boards, and also in accordance with
New York State Office of Mental Health regulations and New
York City Health and Hospitals Corporation regulations.
First-episode BPD (bipolar 1) patients were recruited from
the Comprehensive Psychiatric Emergency Program at
Bellevue Hospital Center, New York. To seek to reduce
variability, all subjects recruited into the study were male.
Recruitment was not restricted by ethnicity. To ensure the
recruitment of first-episode patients prior to the initiation of
medication, an on-call protocol was employed whereby a
member of the study team was notified by the admitting
psychiatrist immediately upon presentation of a potential
subject at the Comprehensive Psychiatric Emergency Program.
Peripheral Expression for Bipolar Classification
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Medicated patients were recruited at Rockland Psychiatric
Center, Orangeburg, NY, its associated outpatient facilities,
and the Rockland County Pomona and Garnerville Clinics.
A Structured Clinical Interview for DSM IV Disorders (SCID)
interview was conducted for all patients to confirm a diagnosis
of BPD. Psychiatric and cognitive symptoms were also
evaluated for first-episode patients, using the Brief Psychiatric
Rating Scale, the Schedule for Assessment of Positive
Symptoms, the Schedule for Assessment of Negative
Symptoms, and the Mini-Mental State Examination.
Male control subjects were recruited from the local hospital
communities and the NKI Volunteer Research Pool; a database
of healthy control subjects also from the local community
interested in participating in research studies. All controls
completed a SCID non-patient interview.
General exclusion criteria for all subjects included current or
recent-infectious diseases, recent physical trauma or surgery,
and chronic immunosuppressant or anti-inflammatory
medication use. For all subjects, a urine toxicology screen was
performed, with urine obtained immediately prior to the
collection of 15mls of whole blood from the anticubital vein.
Subjects recruited into this study were separated into two
groups for analysis; a random 1:1 separation for control
subjects, or for patients, based upon their medication status.
For the first analysis step (feature selection for transcript
enrichment, see below in Data Analysis) samples from the
three never-medicated BPD patients and 13 controls were
employed. Step two (the training, model-building and cross-
validation paradigm), utilized samples from all medicated
patients (n=26), and the remaining 12 control subjects (as
described further below).
Blood Sample Processing and Microarray Hybridization
Immediately after blood collection, PBLs were isolated by
lysis of red cells, centrifugation and washing, according to
standard protocols (Qiagen Inc., Valencia, CA, USA). Blood
samples were immediately split into two; an “A” and replicate
“B” sample (thus two separate RNA extractions, cDNA and
cRNA syntheses and array hybridizations were performed).
Purified white blood cell lysates were stored at -70°C prior to
RNA extraction. The RNA quality of all samples was assessed
using an 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA), and an RNA Integrity Number (RIN)< 7.0 was used
to determine sample degradation, and those samples
discarded. 1ug of total RNA was employed as a template for
cDNA synthesis, using an oligo-dT primer and Reverse
Transcriptase enzyme (Life Technologies Inc., Carlsbad, CA,
USA). Purified cDNA was employed as a template to generate
biotin labeled cRNA, using an RNA Transcript labeling kit
(Enzo Life Sciences Inc., Farmingdale, NY, USA). The quality
of each final cRNA fragmented product was also assessed via
the Bioanalyzer. All samples were considered of sufficient
quality, and were thus fragmented and hybridized to
U133plus2.0 microarrays (Affymetrix Inc., Santa Clara, CA,
USA) at the Yale University Affymetrix facility (via the NIH
Neuroscience Microarray Consortium project, http://
arrayconsortium.tgen.org/), using standard protocols. MIAME
compliant microarray data has been deposited into the NCBI
GEO database, accession number GSE46449.
Data Collection and Quality Control Assessment
To perform an initial assessment of sample quality,
Affymetrix Cel files generated from the scanned microarrays
were analyzed by the MAS5.0, algorithm in the Genechip
Operating Software (GCOS-Affymetrix Inc, Santa Clara CA,
USA), and expression intensity values obtained using a scaling
factor of 100. The presence of contaminating globin transcripts
and RNA degradation was evaluated by determining the
percentage of present calls (the number of transcripts found to
be expressed in leukocytes), and assessment of the 3’/5’ ratios
of the control genes beta-actin and GAPDH. In our dataset,
only three of the arrays had levels of low global expression as
determined by percent present calls over the entire array of
<40% (38.8%, 39.3% and 39.9% for the flagged samples),
however all arrays were within a 10% range of present calls.
No arrays were flagged for high 3’/5’ ratios of the control
genes.
To evaluate the hybridization signal comparability within and
across arrays, Cel files were also evaluated using ‘affy’,
‘simpleaffy’ and ‘affyPLM’ Bioconductor packages [34–37],
through the R programming system [38]. Quality assessment
measures were performed for randomized batches of
microarrays (8-12 arrays per batch), including evaluation of the
raw log-intensity signal distribution (via boxplots and density
histograms), evaluation of intensity-dependent biases (via M-A
plots), determination of spatial biases (via visualization of 2-D
pseudo-images based on probe-level model residuals (the
weights used by Robust Multichip Analysis (RMA) to address
outliers in the data), and evaluation of probe-set homogeneity
(via normalized unscaled standard error plots). No microarrays
were flagged for issues with signal comparability.
For diagnostic group classification, Cel files were imported
into the BRBArray Tools package version 3.8.1 [39], and
converted to normalized intensity values using the Almost RMA
(aRMA) algorithm [40], which uses a background correction on
the Affymetrix perfect match data, then applies a quantile
normalization and finally summarizes the probe set information
by using Tukey’s median polish algorithm (with log
transformation). aRMA (which is employed over RMA when
large numbers of microarrays are present in the data collection
process), has greater sensitivity and specificity for determining
differential gene expression, when compared to, for example
MAS5.0 [40].
The quality of sample replication was then assessed via
three methods: unsupervised average-linked hierarchical
clustering of the entire transcriptome, global pairwise analysis,
and a calculation of the expression differences of a single
control gene between replicates. Where a pair of replicates (the
“A” sample and replicate “B” sample) failed assessment in at
least two of the measures (replicate samples did not cluster
together, and/or global pairwise comparison Spearman’s
rho<0.985, and/or control gene expression log2A–log2B ± 2.3
SD from the mean), the replicate “B” sample was removed from
further analysis.
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Data Collection of the Independent Test Cohort
We also investigated an independent test subject sample,
collected by Matigian et al. [41], (data accessible at NCBI GEO
database [42], accession GSE7036). The sample consisted of
three medicated patients with BPD (bipolar 1 with psychotic
features), and their three discordant twins. For each subject a
lymphoblastoid cell line (LCL) had been established from whole
blood [41], RNA extracted and processed for hybridization to
Affymetrix U133plus2.0 microarrays (the same platform
employed for our enrichment, training and replication samples).
Expression data from a LCL was considered to be related to
that of PBLs, thus representing a useful and completely
independent sample on which to test the predictor gene-model.
Cel files for the six subjects were downloaded from the GEO
database, imported into BRB-Array Tools, and normalized
expression values generated using aRMA as described above.
Data Analysis
Analysis of subject group characteristics was conducted
using SAS (Version 9.1). Group differences were tested using
the Satterthwaite t-test or ANOVA with a correction for multiple
testing (assuming normality of continuous variables), and using
the χ2 or Fisher exact test where the expected cell size was <5
(categorical variables).
Figure 1A depicts the data analysis strategy. A class
comparison algorithm was initially employed in a non-
conservative feature selection; to both remove irrelevant and
redundant features from the data, and importantly to enrich for
disease-related differential transcription not driven by
medication effects. The algorithm was set to identify transcripts
that were differentially expressed among the two classes of the
enrichment sample cohort (the three never medicated BPD
subjects plus 13 of the control subjects selected at random),
using a random-variance t-test [43]. Transcripts were included
if their unadjusted p-value was less than 0.05.
Using the enriched transcript set (n=9550), we developed an
expression model to predict the class of subjects in the training
sample cohort (26 medicated patients and the remaining 12
controls). The BRB-Array Tools package simultaneously
performs and reports model statistics based upon seven well-
known classification algorithms (for BRB-Array Tools Users
Guide see 39). Each classifier was set to incorporate genes
based upon a Support Vector Machine Recursive Feature
Elimination (SVM RFE), which involves an iterative process of
removing transcripts with the lowest weight for each prediction
method, until the desired number of transcripts are left (using
the default setting of n=10). We reasoned that use of an RFE
would ultimately generate a model that, if sensitive and
specific, could be developed into a realistic clinical biomarker
test assaying only a small number of gene transcripts. Class
prediction of the enrichment, replicate and test cohorts was
carried out as described above, except that the classifiers
incorporated only the 10 genes from the original prediction
model.
The 10-gene model was validated for the training cohort
using a leave-one-out cross-validation (LOOCV) design, as
described by Simon et al. [44],). For studies with small n, it has
been suggested that validation of prediction error rates using a
simple split-sample design has the potential for bias [44–46].
LOOCV is an alternative and robust form of error rate validation
that works well for small samples [45], and encompasses an
iterative process, whereby one sample at a time is omitted from
the analysis. For the sample omitted, the entire analysis is
repeated from scratch, including the RFE determination of
genes predicted from the n-1 training cohort. The 10-gene
predictor is then applied to the sample that was omitted, and
the LOOCV reports whether that prediction was correct or not.
The process of omission, model building, and testing, is
repeated for every sample [39].
For all cohorts (training, enrichment, replicate, and test) we
also evaluated whether the error rate estimate for our model
was significantly less than one would expect by chance, based
upon 1000 random permutations. The significance level is the
proportion of the random permutations that gave an error rate
no greater than the error rate obtained with the real data. Thus,
for example, when p=0.015, only 1.5% of the 1000
permutations, by chance, gave a class prediction equivalent to
or better than the one obtained on the actual dataset.
Concordances with Brain Expression
CNS expression levels of the 10 genes in the predictor were
obtained from the brain collection microarray studies published
by the Stanley Medical Research Institute (SMRI) [47]. The
brain collections consist of the Consortium Collection
(BA46/10, BA6, BA8/9 and cerebellum from 15 subjects with
BPD and 15 unaffected controls), and the Array Collection
(BA46 tissue from 35 BPD and 35 controls). The published
data summarizes global gene expression from both collections,
over 12 individual microarray studies and across 6 different
microarray platforms. We considered that due to the controlled
nature of the brain sampling and study design [47], use of this
gene expression data would be robust with limited
experimental error. Gene expression was considered
concordant between brain and blood if the direction of
expression between BPD and controls was consistent between
the SMRI data and that of the replication sample cohort (as this
sample contained all subject groups), with SMRI p-values
reported.
Results
Three first-episode, never-medicated BPD patients and 26
medicated BPD patients were recruited into the study. 25
healthy control subjects were also recruited (see Table 1). As
shown in Table 1 there were no differences between subject
groups on collected demographic variables, except age: there
was a trend for medicated patients to be older at the time of
blood draw when compared to control subjects. Medicated
patients received a wide-range of antipsychotic, mood
stabilizing, and antidepressant medications (Table 2). A SCID
non-patient interview was conducted for all controls, and none
reported symptoms from modules A-D, except for two control
subjects, one of whom had a single episode of depressive
disorder not otherwise specified, and the other a brief past
depressive episode. A urine tox screen was performed for all
subjects: only one subject, a first-episode patient, was found to
Peripheral Expression for Bipolar Classification
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Figure 1.  Experimental Strategy and Gene Expression Data for the 10-Gene Predictor Model.  A: This panel depicts the study
design and order of experimental analysis.
B: Box plot of log expression data for each of the 10 genes in the model developed on the training sample cohort. The horizontal
line within each box represents the group median (BPD or C) for each gene (genes 1-10). The box indicates the interquartile range
(IQR), the whiskers represent 25th and 75th percentiles of the data, and outliers are depicted as circles. 84% of the classes were
correctly predicted using this 10-gene model in a DLDA (p<0.001), with 89% sensitivity and 75% specificity.
C: Log expression data of the enrichment sample cohort for each of the 10 genes. 88% of the sample were correctly predicted, with
a sensitivity of 67% and specificity of 92% (p=0.015).
D: Log expression data of the replicate samples for each of the 10 genes. Six of the control subjects with B samples in the
replication sample were originally randomly sampled to the training sample, and eight originally randomly sampled to the enrichment
sample. 88% of the replicate samples were correctly predicted, with a sensitivity of 90% and specificity of 86% (p<0.001).
Concordance between replicates (for each of the 34 individual subjects with a replicate sample, class prediction of the A replicate =
class prediction of the B replicate), was greater than 85%.
Key: BPD= bipolar disorder patients; C=control subjects; NM= Never-Medicated, DLDA= Diagonal Linear Discriminant Analysis.
Key to Gene List (Probeset ID, Gene Symbol, description):
Gene 1: 212282_at, TMEM97, transmembrane protein 97.
Gene 2: 236769_at, LOCI158402, Hypothetical protein LOCI158402.
Gene 3: 231798_at, NOG, noggin.
Gene 4: 1568983_a_at, unknown transcript, unknown.
Gene 5: 1560527_at, NF-E4, transcription factor NF-E4.
Gene 6: 208304_at, CCR3, chemokine (CC motif) receptor 3.
Gene 7: 230000_at, RNF213, ring finger protein 213.
Gene 8: 225252_at, SRXN1, sulfiredoxin 1 homolog.
Gene 9: 210425_x_at, GOLGA8B, golgi autoantigen, golgin subfamily a, 8B.
Gene 10: 227884_at, TAF15, TAF15 RNA polymerase II, TATA box binding protein (TBP)- associated factor, 68kDa.
doi: 10.1371/journal.pone.0069082.g001
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be positive (for Tetrahydrocannabinol). This first-episode
patient also reported taking 60mg of Adderall (a psycho-
stimulant), daily, two weeks prior to admission and participation
in the study. The characteristics of the three discordant twin
pairs, employed in the independent test set and taken from
[41], are shown in Table 3.
A sufficient blood sample was obtained from 41 subjects
(including all first-episode patients) for complete sample
replication. Thus, ninety-five leukocyte samples (the 41
subjects with replicate samples, plus an additional thirteen
subject samples) were processed to completion and hybridized
to U133plus2 microarrays. All samples passed checks for RNA
quality and quality controls within and between arrays. The
quality of sample replication was also assessed: Where a pair
of replicates (A and B replicated samples from the 41 subjects)
failed assessment in at least two of the measures, the B
sample was removed from further analysis (n=0 first-episode
patients, n=3 medicated patients, and n=4 controls).
In the field of computationally extensive machine learning,
the need to reduce irrelevant complexity of the data is well
known. Class prediction [48], a technique based upon use of
supervised leaning algorithms that can utilize microarray data
to classify between two diagnostic classes, is no exception.
Thus, to reduce dimensionality of the dataset we performed a
simple feature selection: A class comparison analysis [48] was
employed to refine a subgroup of transcripts significantly
differentially expressed (p<0.05) between the classes of our
“enrichment” subject group, which consisted of the never-
medicated BPD patients and a subset of the control subjects
(see Figure 1A). We hypothesized that the resultant transcript
list (n=9550) would be enriched for disease-related differentially
expressed transcripts that were not driven by medication
effects. The enriched gene set was then employed in a class
prediction of subjects in the separate training sample: 26
medicated BPD patients and the remaining 12 control subjects.
Specifically, we developed a gene prediction model that utilized
a SVM-RFE algorithm to identify 10 genes that could predict
the class of the training samples. Expression levels of the 10-
gene predictor are shown in Figure 1B. For validation of our
model, and in order to avoid reducing the size of our training
sample further (as would be required for a split-sample
validation), we employed a LOOCV technique. The cross-
validated error rate, ranged from 0.18 to 0.13 based upon the
classification algorithm employed, and all were unlikely to occur
by chance: Compound Covariate Predictor (0.18, p=0.004);
Diagonal Linear Discriminant Analysis (0.16, p<0.001); 1-
Nearest Neighbour (0.13, p,0.001); 3-Nearest Neighbours
(0.13, p<0.001); Nearest Centroid Correct (0.16, p=0.001);
Support Vector Machine (0.18, p=0.004); and Bayesian
Compound Covariate Predictor (0.17, p=0.004).
Diagonal Linear Discriminant Analysis (DLDA), applies a
discriminate transformation to the expression data, using a
weighted linear combination of log-intensities for genes,
whereby genes in which larger values of the log-ratio pre-
dispose to class 2 and have weights of one sign, whereas
genes in which larger values of the log-ratios pre-dispose to
class 1 have weights of the opposite sign. The univariate t-
statistics for comparing the classes are used as the weights
(thus by definition, more weight is given to genes with a high-
signal-to-noise-ratio), and employed in the RFE. It has been
suggested that because DLDA ignores correlations among
genes it is particularly useful in avoiding data overfitting, with
the lowest reported cross-validated error rates following direct
comparison of multiple prediction algorithms [49]. Based upon
this attribute, we chose to focus further exploration of the 10-
gene predictor using only the DLDA classifier. DLDA correctly
predicted the diagnostic group of 84% of the training sample
set (see Table 4). Interestingly, the two control subjects who
reported depressive episodes were both predicted to belong to
the bipolar group, and after removing these subjects, the
predictor yielded a sensitivity and specificity of 89% and 90%,
respectively. We also examined the effect of utilizing the SVM-
RFE algorithm to identify a predictive model containing n=5, 15,
20, 25 to n=40 genes. None reached the level of sensitivity and
specificity achieved by the initial and default n=10 model, and
so only this model was carried forward in the analysis.
We tested our predictor by employing the 10-gene model in a
DLDA of the original enrichment sample dataset (n=3 first-
episode patients and n=13 controls), and in addition, to assess
experimental reproducibility, the replicate samples (the B
replicates from 34 subject): 88% of sample diagnostic classes
were correctly predicted for both the enrichment and replicate
datasets (p=0.015 and p<0.001 respectively, see Figure 1C
and 1D), and the concordance between predictions of the
replicate samples was greater than 85%.
Table 1. Characteristics of Study Subjects.
Characteristic NM-BPD BPD Controls
n 3 26 25
Ethnicity, % (n)    
African American 0 (0) 16 (4) 28 (7)
Caucasian 67 (2) 80 (21) 60 (15)
Hispanic 0 (0) 4 (1) 4 (1)
Asian 33 (1) 0 (0) 8 (2)
Age, years, mean (SD) 33.3 (4.0) 40.8* (14.4) 32.5 (9.7)
Age at First Hospitalization, years    
Mean (SD) 33.3 (4.0) 25.0 (13.13)  
Treatment Setting, % (n)a    
Inpatient 100 (3) 53.9 (14)  
Outpatient 0 (0) 46.1 (12)  
With Psychotic Features, % (n) 100 (3) 42.4 (11) 0 (0)
BPRSb Total Symptoms, mean (SD) 39 (5.3)   
SAPSc Total Symptoms, mean (SD) 29.7 (16.3)   
SANSd Total Symptoms, mean (SD) 15.7 (5.5)   
MMSEe Total Symptoms, mean (SD) 28.7 (0.6)   
* F(2,51)=3.11, p 0.053. There were no other significant differences of demographic
variables across the three groups (ethnicity), or patient groups (age at first
hospitalization and treatment setting).
a. Outpatient includes outpatients living on hospital grounds and in the community
b. Brief Psychiatric Rating Scale
c. Schedule for Assessment of Positive Symptoms
d. Schedule for Assessment of Negative Symptoms
e. Mini-Mental State Examination
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Finally, we performed exploratory validation of our 10-gene
predictor using data from an independent test sample: LCL
expression data obtained from three pairs of monozygotic twins
discordant for BPD [41]. 83% of these samples were correctly
predicted with a specificity of 100% and sensitivity of 67% (only
one of the 6 subjects, the BPD twin from pair 3, was incorrectly
predicted). However, 18% of the 1000 random permutations
correctly predicted five or more of the samples (LOOCV
permutation p=0.18). This elevated prediction error-rate may
highlight differences between the tissue sources (such as the
need to transform the cells) that could introduce gene
expression variation in the predictor genes and mask the BPD
biomarker profile, or may reflect the small sample size.
The 10 genes from the predictor are summarized in Table 5.
Interestingly, 70% map to loci previously linked to BPD [50]. To
examine the implications of this finding, we randomly chose
and mapped to the human genome 500 transcripts from the
microarray. Although 203 (40%) also mapped to linkage
regions, there was a trend for genes in the predictor to be
associated with BPD loci, compared to the 500 randomly
permuted genes (p=0.061). As also shown in Table 5, of the
genes that were expressed in the brain and measured in the
SMRI microarray studies (n=6), four were co-regulated
between brain and blood, which is consistent with previous
data reporting a moderate correlation between global CNS and
blood gene expression, with approximately 50% of psychiatric
illness relevant genes tested expressed in both tissues [51].
Discussion
Recognizing the need for a biological assay that could help
diagnose BPD and potentially define susceptibility at an early
stage, we and others [21,23], have successfully developed a
peripheral gene expression biomarker profile that can
accurately classify healthy controls from patients with BPD who
are currently receiving or have previously received
antipsychotic or mood stabilizing medication, which has both
high sensitivity and specificity, with a low cross-validated
prediction error rate.
Important features of a biomarker include high sensitivity and
specificity, with the need to be able to test and validate the
predictor on both replication and independent cohorts.
Moreover, the expression biomarker must not be dependent on
other group differences, such as medication status; to date the
majority of gene expression class prediction studies for
psychiatric illness have identified gene profiles that classify
between medicated patients and unmedicated control subjects.
Therefore, utilizing the 10-gene predictor trained upon
medicated patients and controls, we explored whether we were
also able to predict the class of the enrichment cohort, which
included the first-episode patients and a separate group of
controls. We observed high class prediction specificity (92.3%),
with a sensitivity of 66.6%, and this result was unlikely to occur
by chance (p=0.015). One caveat to this approach, and due to
our small sample, is the use of the enrichment set to both
perform the feature section (reducing the dataset from 54,675
to 9550 transcripts), and then to test the 10-transcript model
developed upon the training sample. While the purpose of the
feature selection was to enrich for disease-related differential
expression that was not driven by medication status, the
downstream testing of the 10-gene model in this cohort should
not be considered completely independent from the model-
training process. Thus, even though the 10-gene model
represents only 0.1% of the total enriched dataset, the error
rates may be positively biased due to the use of incomplete
Table 2. Medication Profiles of Study Subjects.
Medication NM-BPD BPD Controls
n 3 26 25
Antipsychotics, % (n)    
None 100 (3) 27 (7) 100 (25)
Atypical Only  50 (13)  
Typical Only  15 (4)  
Both  8 (2)  
Dose, Median (IQR)    
CPZ equivalentsa 0 (0) 479.1 (399.8) 0 (0)
Aripiprazole (n=3)  3, 20 (20)  
Clozapine (n=1)  300 (0)  
Haloperidol (n=1)  20 (0)  
Olanzapine (n=4)  25 (15)  
Quetiapine (n=9)  450 (100)  
Risperidone (n=3)  5.4 (2.9)  
Ziprasidone (n=2)  160 (0)  
Mood Stabilizers, % (n) 0 (0) 81 (21) 0 (0)
Dose, Median (IQR)    
Lithium (n=9)  750 (300)  
Divalproex (n=6)  1125 (1000)  
Gabapentin (n=3)  900 (600)  
Lamotrigine (n=6)  175 (50)  
Oxcarbazepine (n=1)  1200 (0)  
Valproic Acid (n=1)  2000 (0)  
Antidepressants, % (n) 0 (0) 46.2 (12) 0 (0)
Dose, median (IQR)    
Bupropion (n=1)  200 (0)  
Citralopram (n=1)  20 (0)  
Venlafaxine (n=2)  112.5 (75)  
Fluoxetine (n=3)  20 (20)  
Sertraline HCl (n=3)  100 (150)  
Trazodone (n=2)  125 (50)  
a. Chlorpromazine-equivalent dose
Table 3. Characteristics of the Monozygotic twin pairs [41].
Characteristic Twin pair 1 Twin Pair 2 Twin Pair 3
n 2 2 2
Age at onseta 19 19 18
Ageb 55 23 38




a. BPD twin only
b. Age at blood draw
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cross-validation [46]. Nonetheless, assay of first-episode
patients who have never received antipsychotic or mood
stabilizing medication (the first transcriptome level study of
never-medicated BPD patients) supports the peripheral
biomarker approach for early BPD diagnosis.
To assess the ability to replicate our findings we
independently assayed each subject sample in duplicate. We
correctly identified the diagnostic class of 88% of the subjects
in the replicate cohort with a very low predicted error. Only five
samples did not give identical class predictions across
replicates. While this result was not unexpected, the high level
of experimental replication suggests that the PBL gene
predictor can resist technical variation.
Validation of gene predictor models is an important step
during determination of the non-biased error rate. This can be
achieved using a cross-validation design (such as LOOCV), or
alternatively it is also common in the field of class prediction to
employ a split-sample design, whereby one group of subject
samples are employed in training of the predictor, and a
completely independent group employed to singularly test the
model. While this may be a powerful approach, a meaningful,
unbiased predictor requires that both training and test sets are
sufficient in size as to be representative of their original
population distributions; for example, Molinaro et al., showed
that only from analysis of 120 samples or more did the rates of
error bias from the split-sample design reduce to rates
observed using LOOCV [45], and the spilt-sample approach is
not recommended for cohorts of size less than 150 [52]. Thus,
due to our sample size, further separation of patients and
control samples to derive a test sample would likely add bias to
the predicted error rates [45]. Therefore, we obtained an
independent microarray dataset consisting of transformed
lymphocyte expression data from three pairs of monozygotic
twins discordant for BPD [41]. Methods of subject
ascertainment, recruitment, blood sampling and processing
varied dramatically between our study and that reported by
Matigian et al., however only 1 subject from that study (a BPD
twin) was incorrectly assigned to their diagnostic group using
our 10-gene predictor (83% correct assignment, 100%
specificity, and 66.6% sensitivity). Although this is a promising
result, the non-significant LOOCV does not allow us to rule out
that chance contributed to this result, and care must be taken
when interpreting error rates from small validation sets [44].
Additional analyses of larger independent test sets of leukocyte
expression, particularly expression data obtained from first-
episode never-medicated patients, is warranted to confirm our
findings and we consider the 10-gene classifier as only a first
iteration of a predictive model for BPD diagnosis.
Even with the knowledge that a final biomarker profile for
BPD needs further development, the ten genes in this reported
model are potentially relevant to BPD biomarker diagnosis; the
majority are linked with BPD and when expressed, are co-
regulated in the CNS. Work by others has further highlighted
their potential importance to neuropsychiatric disorders,














(n=38) 23/26 9/12 84% 89% 75% p<0.001
Enrichment
(n=16) 2/3 12/13 88% 67% 92% p=0.015
Replication
(n=34) 18/20 12/14 88% 90% 86% p<0.001
Test (n=6) 2/3 3/3 83% 67% 100% p=0.18
a. Leave-One-Out-Cross-Validation permutation p-value, based upon 1000
permutations.
Table 5. The 10-gene Predictor.
Gene Numbera Affymetrix probeset ID Gene Symbol Description Chromosome locationb Concordant Brain expressionc
Gene 1: 212282_at TMEM97 transmembrane protein 97 17q11.2* Downregulated in BPD: Consortium (p=0.025)d
Gene 2: 236769_at LOCI158402 Hypothetical protein LOCI158402 9q32* Downregulated in BPD: Consortium (p=0.23)
Gene 3: 231798_at NOG noggin 17q22 No changee
Gene 4: 1568983_a_at unknown Unknown transcript. 15q21.2 Data not available
Gene 5: 1560527_at NF-E4 transcription factor NF-E4 7q22.1* Data not available
Gene 6: 208304_at CCR3 chemokine (CC motif) receptor 3 3p21.3* Downregulated in BPD: Array (p=0.15)e
Gene 7: 230000_at RNF213 ring finger protein 213 17q25.3* No change
Gene 8: 225252_at SRXN1 sulfiredoxin 1 homolog 20p13* Not expressed
Gene 9: 210425_x_at GOLGA8B golgi autoantigen 15q14 Data not available
Gene 10: 227884_at TAF15 TAF15 RNA polymerase II 17q11.1-q11.2* Upregulated in BPD: Array (p=0.0108)
a. From Figure 1b–1d
b. * denotes loci previously linked to BPD [48].
c. Data from the Replication sample compared to microarray expression data from the SMRI [46]. Only the brain collection(s) with concordant expression are noted, no
change between BPD patients and controls was observed for the collections not described, except for Gene 1
d. : the collections showed an opposite trend of differential expression, array collection upregulated in BPD, p 0.072).
e. SMRI data suggests very low expression in the collections examined.
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including BPD. For example, Noggin (NOG, Gene 3 of the
predictor) is an inhibitor of bone morphogenetic proteins, is
expressed in the CNS [53], and is involved in multiple functions
both during development and in the adult such that knockout
animals have defects in neural tube fusion and joint formation
[54], and noggin-mediated inhibition of BMP signaling has been
reported to induce improvements in neurogenesis and
cognition in mice [55]. The chemokine (CC motif) receptor 3
transcript (Gene 6), which encodes a G-protein-coupled
receptor [56] was previously found to be downregulated in
postmortem dorsolateral prefrontal cortex tissue from patients
with bipolar disorder [57], and peripheral blood expression of
RNF213 (Gene 7, the ring finger protein 213) was found to
correlate with response to the atypical neuroleptic risperidone
by children with autism spectrum disorders [58]. Supporting our
findings, Beech et al., who identified genes differentially
expressed between BPD patients and controls, also found
upregulation of the SRXN1 gene (Gene 8, sulfiredoxin 1
homolog, whose encoded product reduces oxidant stress-
generated cysteine-sulfinic acid), in PBLs of BPD patients,
including unmedicated patients, when compared to controls
[31].
Regarding limitations, there were a number of caveats to this
study, such as the potential for confounding effects of age on
the biomarker profile, and the use of only males in the study
reducing generalizability. With regards to age, although there
was a trend for medicated patients to be older than controls,
with age thus potentially driving the medicated patient trained
predictor, first-episode patients were not different in age to
controls, and the ages of the independent cohort were matched
due to the nature of the twin study. Concerning generalizability,
four of the independent sample twin cohort were female, of
which one, a BPD patient, was the only subject in this cohort to
be incorrectly classified. Further study of PBL expression in
females is warranted however, to determine if gender
differences contributed to this result or if the incorrect
prediction simply arose due to the different tissue sources and
experimental procedures, such as the transformation process
to obtain LCLs from this subject.
In general, the 10-gene predictor had high rates of specificity
across study cohorts, suggesting that a positive prediction of
BPD translates to a high probability of the presence of the
illness. In clinical practice such a test would, for example,
reduce levels of side effects from unnecessary mood stabilizer
treatment due to overdiagnosis, but may result in missed
opportunities to treat patients due to the lower sensitivity of the
assay. Continuing this work, via the necessary assay of
additional first-episode BPD patients and matched controls for
model validation on completely independent test cohorts, and
also cohorts of patients with unipolar depression, may help to
develop and define the true utility of this PBL gene predictor.
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